The role of clusterin in amyloid-β-associated neurodegeneration

JAMA Neurology

Volumn 71, Issue 2, 2014, Pages 180-187

  Desikan, Rahul S ^a   Thompson, Wesley K ^b   Holland, Dominic ^c   Hess, Christopher P ^d   Brewer, James B ^a,c   Zetterberg, Henrik ^e,f   Blennow, Kaj ^e   Andreassen, Ole A ^b,g   McEvoy, Linda K ^a   Hyman, Bradley T ^h   Dale, Anders M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY OF OSLO   (Norway)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; CLUSTERIN; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; CANADA; CLINICAL DEMENTIA RATING; CONTROLLED STUDY; ENTORHINAL CORTEX; FEMALE; HIPPOCAMPUS; HUMAN; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NERVE DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; TEMPORAL LOBE; UNITED STATES;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; CLUSTERIN; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; NEURODEGENERATIVE DISEASES; PEPTIDE FRAGMENTS;

EID: 84893870491     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2013.4560     Document Type: Article

References (29)

1. May PC, Johnson SA, Poirier J, Lampert-Etchells M, Finch CE. Altered gene expression in Alzheimer's disease brain tissue. Can J Neurol Sci. 1989;16(4) (suppl):473-476.
2. McGeer PL, Kawamata T, Walker DG. Distribution of clusterin in Alzheimer brain tissue. Brain Res. 1992;579(2):337-341.
3. Lidström AM, Bogdanovic N, Hesse C, Volkman I, Davidsson P, Blennow K. Clusterin (apolipoprotein J) protein levels are increased in hippocampus and in frontal cortex in Alzheimer's disease. Exp Neurol. 1998;154(2):511-521.
4. Nilselid AM, Davidsson P, Nägga K, Andreasen N, Fredman P, Blennow K. Clusterin in cerebrospinal fluid: analysis of carbohydrates and quantification of native and glycosylated forms. Neurochem Int. 2006;48(8):718-728.
5. Yu JT, Tan L. The role of clusterin in Alzheimer's disease. Mol Neurobiol. 2012;45(2):314-326.
6. Schrijvers EM, Koudstaal PJ, Hofman A, Breteler MM. Plasma clusterin and the risk of Alzheimer disease. JAMA. 2011;305(13):1322-1326.
7. Thambisetty M, Simmons A, Velayudhan L, et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry. 2010;67(7):739-748.
8. Freeman SH, Kandel R, Cruz L, et al. Preservation of neuronal number despite age-related cortical brain atrophy in elderly subjects without Alzheimer disease. J Neuropathol Exp Neurol. 2008;67(12):1205-1212.
9. Bobinski M, de Leon MJ, Wegiel J, et al. The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease. Neuroscience. 2000;95(3):721-725.
10. Blennow K, Zetterberg H, Fagan AM. Fluid biomarkers in Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2(9):a006221.
11. Desikan RS, McEvoy LK, Thompson WK, et al; Alzheimer's Disease Neuroimaging Initiative. Amyloid-β associated volume loss occurs only in the presence of phospho-tau. Ann Neurol. 2011;70(4):657-661.
12. Desikan RS, McEvoy LK, Thompson WK, et al; Alzheimer's Disease Neuroimaging Initiative. Amyloid-β-associated clinical decline occurs only in the presence of elevated p-tau. Arch Neurol. 2012;69(6):709-713.
13. Desikan RS, McEvoy LK, Holland D, et al; Alzheimer's Disease Neuroimaging Initiative. Apolipoprotein E epsilon4 does not modulate amyloid-β- associated neurodegeneration in preclinical Alzheimer disease. AJNR Am J Neuroradiol. 2013;34(3):505-510.
14. Storandt M, Head D, Fagan AM, Holtzman DM, Morris JC. Toward a multifactorial model of Alzheimer disease. Neurobiol Aging. 2012;33(10):2262- 2271.
15. Stricker NH, Dodge HH, Dowling NM, Han SD, Erosheva EA, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative. CSF biomarker associations with change in hippocampal volume and precuneus thickness. Brain Imaging Behav. 2012;6(4):599-609.
16. Alzheimer's Disease Neuroimaging Initiative. Biomarkers Consortium Data Primer Version December 28, 2011. La Jolla, CA: Alzheimer's Disease Neuroimaging Initiative.
17. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al; Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer's Disease Neuroimaging Initiative subjects. Ann Neurol. 2009;65(4):403-413.
18. Fennema-Notestine C, Hagler DJ Jr, McEvoy LK, et al; Alzheimer's Disease Neuroimaging Initiative. Structural MRI biomarkers for preclinical and mild Alzheimer's disease. Hum Brain Mapp. 2009;30(10):3238-3253.
19. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-259.
20. Desikan RS, Ségonne F, Fischl B, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31(3):968-980.
21. Fischl B, Salat DH, Busa E, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33(3):341-355.
22. Holland D, Dale AM; Alzheimer's Disease Neuroimaging Initiative. Nonlinear registration of longitudinal images and measurement of change in regions of interest. Med Image Anal. 2011;15(4):489-497.
23. Holland D, McEvoy LK, Dale AM; Alzheimer's Disease Neuroimaging Initiative. Unbiased comparison of sample size estimates from longitudinal structural measures in ADNI. Hum Brain Mapp. 2012;33(11):2586-2602.
24. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412-2414.
25. Nuutinen T, Suuronen T, Kauppinen A, Salminen A. Clusterin: a forgotten player in Alzheimer's disease. Brain Res Rev. 2009;61(2):89-104.
26. Thambisetty M, An Y, Kinsey A, et al. Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment. Neuroimage. 2012;59(1):212-217.
27. Killick R, Ribe EM, Al-Shawi R, et al. Clusterin regulates β-amyloid toxicity via Dickkopf-1-driven induction of the wnt-PCP-JNK pathway [published online November 20, 2012]. Mol Psychiatry. doi:10.1038/mp. 2012.163.
28. De Mattos RB, O'Dell MA, Parsadanian M, et al. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2002;99(16):10843-10848.
29. Lambert MP, Barlow AK, Chromy BA, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A. 1998;95(11):6448-6453.